Bayhill Therapeutics Raises an Additional $15.8 Million
News | 04. 10. 2006
Bayhill Therapeutics Inc. has begun dosing patients with BHT-3009, the company’s experimental drug candidate, in a Phase II company sponsored trial for multiple sclerosis. The Phase II study is a multi-center, double-blind, placebo-controlled evaluation with an MRI endpoint. In a related development, current investors indicated strong support for Bayhill’s antigen-specific tolerance platform by raising an additional $15.8 million in private equity. The company has now closed its Series B round totaling $51.2 million.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.